Do Drug Metabolism and Pharmacokinetic Departments Make Any Contribution to Drug Discovery?
- 113 Downloads
The alignment of drug metabolism and pharmacokinetic departments with drug discovery has not produced a radical improvement in the pharmacokinetic properties of new chemical entities. The reason for this is complex, reflecting in part the difficulty of combining potency, selectivity, water solubility, metabolic stability and membrane permeability into a single molecule. This combination becomes increasingly problematic as the drug targets become more distant from aminergic seven-transmembrane-spanning receptors (7-TMs). The leads available for aminergic 7-TMs, like the natural agonists, are invariably small molecular weight, water soluble and potent. Even moving to 7-TMs for which the agonist is a peptide invariably produces lead matter that is less drug-like (higher molecular weight and lipophilic). The role of drug metabolism departments, therefore, has been to guide chemistry to obtaining adequate, rather than optimal, pharmacokinetic properties for these ‘difficult’ drug targets.
A consistent belief of many researchers is that a high value is placed on optimal, rather than adequate, pharmacokinetic properties. One measure of value is market sales, and when these are examined no clear pattern emerges. Part of the success of amlodipine in the calcium channel antagonist sector must be due to its excellent pharmacokinetic profile, but the best-selling drugs among the angiotensin antagonists and β-blockers have a much greater market share than other agents with better pharmacokinetic properties. Clearly, many other factors are important in the successful launch of a medicine, some reflected in the manner the compound is developed and the subsequent structure of the labelling.
Overall, therefore the presence of drug metabolism in drug discovery has probably contributed most by allowing ‘difficult’ drug targets to be prosecuted, rather than by guiding medicinal chemists to optimal pharmacokinetics. These ‘difficult’ target candidates become successful drugs when skilfully developed. There is no doubt that skilful development relies heavily on drug metabolism and pharmacokinetic departments, in this case those with a clinical rather than a preclinical orientation.
KeywordsLosartan Drug Metabolism Amlodipine Ritonavir Indinavir
The authors would like to thank their many colleagues who have asked the question posed in the title on many occasions.
- 2.Pinto DJ, Orwat MJ, Wang S, et al. Discovery of l-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carbox amide (DPC423), a highly potent, selective, and orally bio-available inhibitor of blood coagulation factor Xa. J Med Chem 2001; 44: 566–78PubMedCrossRefGoogle Scholar
- 5.Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics Company, Inc., 2000: 1202–7Google Scholar
- 6.Smith DA, Jones B. Variability in drug response as a factor in drug design. Curr Opin Drug Disc Dev 1999; 2: 33–41Google Scholar
- 14.De Groot MJ, Ackland MJ, Home VA, et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 1999; 42: 4062–70PubMedCrossRefGoogle Scholar